Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (KO2155/6-1)
Medizinische Fakultät, RWTH Aachen University
José Carreras Leukämie-Stiftung (R10/23)
START grant by the Faculty of Medicine in Aachen
Excellence Initiative of the German Federal and State Governments and the German Research Foundation (GSC 111)
Text and Data Mining valid from 2019-04-02
Received: 1 December 2018
Accepted: 13 March 2019
First Online: 2 April 2019
Ethics approval and consent to participate
: Primary patient samples were obtained from patients of the Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation at RWTH Aachen University after written informed consent, as approved by the local ethics committee (EK 127/12 and EK 206/09).
: Not applicable.
: SK has been a member of Advisory Boards for Pfizer, Incyte/Ariad, Novartis, AOP, BMS, and CTI; receives honoraria and travel funding from Novartis, BMS, Pfizer, Incyte/Ariad, and Shire; has received scientific research support from Novartis Foundation, BMS, and Novartis; and has received travel funding by Alexion. THB reports grants from Pfizer and Novartis and served as an advisor for Novartis, Pfizer, and ARIAD during the conduct of the study. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.